CMPS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Compass Pathways partnered with the U.S. Department of Veterans Affairs on an investigational psilocybin studyAug 6, 2026
- Compass Pathways reported six-month data confirming rapid and durable effects in its second Phase 3 trialJul 8, 2026
- Compass Pathways planned to announce new clinical data from two ongoing Phase 3 trialsFeb 17, 2026
- FDA accepted Compass Pathways' IND for PTSD and company hosted PTSD webinarJan 7, 2026
- Compass Pathways' COMP360 psilocybin shows positive efficacy and tolerance resultsSep 2, 2025